A global, family-owned company with headquarters in Europe has offices all around the world. The firm’s venture fund focuses on early stage companies, and positions itself to be a strategic corporate partner to develop and support innovative technologies to commercialization in areas for growth opportunity. The firm’s venture fund typically makes $1-$5 million investments. The firm is seeking 4-5 investments in early-stage companies, start-ups including spinout companies from academia. The firm is geographically agnostic, and is open to investments from all over the world.
The firm is seeking outstanding ideas and promising technologies that are capable of generating a high level of customer interest. Besides early stage projects and seed investments, the firm aims to maximize the value of their entire portfolio, including the development of promising later stage investments and opportunities across all aforementioned the firm’s focus areas. The firm’s interest in Aesthetics comprises an anti-aging focus, including skin rejuvenation, body shaping and modification. The firm is open to all therapeutics, medical devices, and digital health / healthcare IT, as long as the technology serves an unmet need/gap in the aesthetics professionals’ daily practice.
The firm’s Neuroscience perspective includes, but is not limited to the treatment of movement disorders and adjacent indications, while the firm’s consumer healthcare business is open applicable b2b and d2c models for improving consumers’ wellbeing and sustainable quality of life.
The firm take pride in their long-standing commitment to both innovation and continuity. In line with their strategic interests, the firm is open to proactive and long-term engagement with their partners, and hope to provide much more than financial backing.
The firm seeks to directly connect investments to the firm’s global infrastructure by offering access to relevant experts in their scientific research network and providing commercial insights into global market.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment